Wecome Pharmaceutical Co Ltd (300878) — Cash Flow-to-Debt Ratio
Wecome Pharmaceutical Co Ltd (300878) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-1.42 Million could theoretically repay 0% of its total liabilities (CN¥458.37 Million) in one year. See 300878 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wecome Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Wecome Pharmaceutical Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Wecome Pharmaceutical Co Ltd.
Annual Cash Flow-to-Debt Ratio for Wecome Pharmaceutical Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Wecome Pharmaceutical Co Ltd. Check Wecome Pharmaceutical Co Ltd (300878) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | CN¥-27.17 Million | CN¥478.50 Million | ▼ -162.3% |
| 2023 | 0.09x | CN¥58.29 Million | CN¥639.23 Million | ▼ -68.8% |
| 2022 | 0.29x | CN¥146.57 Million | CN¥502.25 Million | ▲ +222.5% |
| 2021 | -0.24x | CN¥-67.74 Million | CN¥284.28 Million | ▼ -236.0% |
| 2020 | 0.18x | CN¥42.81 Million | CN¥244.39 Million | ▼ -44.7% |
| 2019 | 0.32x | CN¥112.76 Million | CN¥356.02 Million | ▼ -25.8% |
| 2018 | 0.43x | CN¥105.57 Million | CN¥247.29 Million | ▲ +155.6% |
| 2017 | 0.17x | CN¥29.00 Million | CN¥173.68 Million | ▼ -82.6% |
| 2016 | 0.96x | CN¥100.15 Million | CN¥104.25 Million | ▲ +197.8% |
| 2015 | 0.32x | CN¥29.63 Million | CN¥91.84 Million | ▼ -33.5% |
| 2014 | 0.49x | CN¥46.01 Million | CN¥94.82 Million | ▲ +35.9% |
| 2013 | 0.36x | CN¥25.98 Million | CN¥72.78 Million | — |